![John Berriman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Berriman
Directeur/Membre du Conseil chez
AUTOLUS THERAPEUTICS PLC
Fortune : 254 939 $ au 31/05/2026
Profil
John Edward Berriman is the founder of Illumina Cambridge Ltd. Mr. Berriman is currently Non-Executive Chairman at Autifony Therapeutics Ltd. since 2011, Chairman at Depixus SAS since 2015, Non-Executive Director at Autolus Ltd., and Lead Independent Director at Autolus Therapeutics Plc since 2014.
Former roles include Non-Executive Chairman at ReNeuron Group Plc from 2015 to 2020, Executive Deputy Chairman at Oxxon Therapeutics, Inc. in 2006, Chairman at MyCartis NV, Deputy Chairman at Algeta ASA in 2008, Chairman at Nxera Pharma UK Ltd. from 2007 to 2015, Chairman at Confo Therapeutics NV from 2016 to 2023, Director at Celltech Group Plc in 1996, Director at Abingworth Management Ltd. from 1997 to 2004, Director at Abingworth LLP from 1997 to 2001, Non-Executive Director at Cytos Biotechnology AG in 2012, Director at Epigenomics AG in 2006, Director at Alnylam Pharmaceuticals, Inc. from 2003 to 2005, Director at Ablynx NV in 2005, Director at Chroma Therapeutics Ltd., Director at Varex Imaging Sweden AB, Director at Amgen Rockville, Inc. from 2006 to 2012, and Director at Micromet, Inc. Education includes undergraduate studies at the University of Cambridge and an MBA from London Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/03/2026 | 136 331 ( 0,08% ) | 254 939 $ | 31/05/2026 |
Postes actifs de John Berriman
| Sociétés | Poste | Début |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Directeur/Membre du Conseil | 01/08/2014 |
Depixus SAS
 Depixus SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops a technology for genetic and epigenetic analysis | Président | 01/12/2015 |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Directeur/Membre du Conseil | - |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops new pharmaceutical treatments treat hearing disorders | Président | 23/08/2011 |
Anciens postes connus de John Berriman
| Sociétés | Poste | Fin |
|---|---|---|
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Président | 29/08/2023 |
| RENEURON GROUP PLC | Président | 10/09/2020 |
Nxera Pharma UK Ltd.
 Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Président | 01/02/2015 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Develops therapeutics for cancer | Directeur/Membre du Conseil | - |
Micromet Inc.
 Micromet Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases | Directeur/Membre du Conseil | 01/01/2012 |
Formation de John Berriman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
68
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
ReNeuron Group Plc
 ReNeuron Group Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and manufactures cell-based therapy products | Health Technology |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Finance |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Commercial Services |
Epigenomics AG
 Epigenomics AG Medical SpecialtiesHealth Technology Engages in the development and commercialization of in vitro diagnostic tests for cancer | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Solexa Ltd.
 Solexa Ltd. BiotechnologyHealth Technology Develops DNA sequencing and array-based life sciences technologies | Health Technology |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Develops and produces antibodies | Health Technology |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Engages in the discovery and development of therapies for the treatment of cancer and inflammation | Health Technology |
Direct Conversion AB
 Direct Conversion AB Medical SpecialtiesHealth Technology Develops and manufactures X-ray imaging components | Health Technology |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures antigen-specific immunotherapy’s to treat patients | Health Technology |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Develops therapeutics for cancer | Health Technology |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology Develops technologies for healthcare personalization needs | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Engages in the development of products for the treatment of cancer | Health Technology |
Nxera Pharma UK Ltd.
Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Health Technology |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops new pharmaceutical treatments treat hearing disorders | Health Technology |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops a technology for genetic and epigenetic analysis | Commercial Services |
Autolus Therapeutics Plc
 Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Micromet Inc.
Micromet Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases | Health Technology |
